Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia

L. Wideroff, M. H. Schiffman, B. Nonnenmacher, N. Hubbert, R. Kirnbauer, C. E. Greer, D. Lowy, A. T. Lorincz, M. M. Manos, A. G. Glass, D. R. Scott, D. R. Scott, R. J. Kurman, J. Buckland, R. E. Tarone, J. Schiller

Research output: Contribution to journalArticlepeer-review

121 Scopus citations

Abstract

An ELISA to detect serum IgG antibody response to human papillomavirus (HPV) type 16 viruslike particles (VLPs) was evaluated in a case-control study of cervical neoplasia, nested within a prospective cohort study. Subjects included 688 controls with continued normal cytology and 152 cases with confirmed incident squamous intraepithelial lesions who were tested for DNA of a broad spectrum of HPV types at cohort enrollment and follow-up. Of controls, 16.6% were seropositive compared with 30.8% and 52.4% of cases with low- and high-grade lesions, respectively. Of HPV16 DNA-negative subjects, 16.5% were seropositive. Seropositivity increased from 22.2% in subjects who were HPV-16 DNA- positive by polymerase chain reaction once only (enrollment or follow-up) to 83.3% in those who were HPV-16 DNA-positive at both time points. These data imply that serum antibody to HPV-16 VLPs is a relatively sensitive indicator of persisting cervical HPV-16 infection.

Original languageEnglish (US)
Pages (from-to)1425-1430
Number of pages6
JournalJournal of Infectious Diseases
Volume172
Issue number6
DOIs
StatePublished - Dec 1995

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia'. Together they form a unique fingerprint.

Cite this